Skip to content
Home/Companies/Biotech/Oculis

Oculis

Biotech·Switzerland·Exited 2023·Held 3yr
Entry
2020
Hold
3yr
Exit
2023

Who owns Oculis?

Oculis was owned by Earlybird Venture Capital through Earlybird Health (2017 vintage) from 2020 to 2023, exited via IPO.

Hand-verified · updated 2026-08-10

Earlybird Venture Capital
Investor
Earlybird Venture Capital
Earlybird Health · 2017 · VC

Key facts

HQSwitzerland
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2023

More from Earlybird Health

Other portfolio companies in the same fund.

Axon Vascular Europe
Active
MedTechUnited Kingdom· 2025
Haya Therapeutics
Haya Therapeutics
Active
BiotechSwitzerland· 2025
Hilo
Hilo
Active
MedTechSwitzerland· 2025
Portal Biotech
Active
BiotechUnited Kingdom· 2025
Rivia
Active
HealthTechSwitzerland· 2025
Gemma Biotherapeutics
Gemma Biotherapeutics
Active
BiotechUnited States· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Oculis

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Oculis.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue